C-反应蛋白致心肌损伤及生物学干预的研究
|
摘要
背景:C-反应蛋白是一种急性时相反应的标志物,属于高度保守的正五聚体血浆蛋白家族,在先天免疫系统中作为模式识别受体发挥功能。急性心肌梗塞(AMI)时,由于心肌缺血、损伤、坏死等病变,可导致血清CRP水平发生变化,已有大量临床资料表明,CRP增高和动脉粥样硬化、急性心肌梗塞预后相关。CRP作为炎症标记物,在心血管事件形成过程中是否仅仅是一个“旁观者”,是否直接参与心血管疾病的发生与发展过程,仍存在争议。近年来,越来越多的体外研究证据表明CRP损伤血管平滑肌细胞,血管内皮细胞,在动脉粥样硬化的发生、发展过程中起着直接作用。有研究发现急性心肌梗塞患者心脏的梗塞区有CRP沉积,而且CRP的含量与梗塞的范围呈正相关。此外,动物实验已证明针对CRP进行治疗,可以防止大鼠心肌梗塞模型中梗塞面积的增加,并且能消除注射人CRP后引起心脏功能紊乱的现象。这些研究提示,CRP可能加重了心肌梗塞的发展,已证明线粒体细胞色素C在心肌梗塞区细胞凋亡过程中发生转移,细胞色素C释放到胞质后可引发caspase活化级联反应,导致细胞死亡,但这些重要蛋白是否参与了C-反应蛋白致心肌损伤过程仍不明确,因此,探讨CRP加重心肌梗塞,致心脏功能紊乱的分子机制,寻找一种针对CRP治疗的更为高效无毒的药物是一项重要的探索性研究领域,引起了研究工作者和临床医生的兴趣和关注。
目的:为探讨CRP对心肌细胞的直接损伤作用和分子机制,寻找一种阻断CRP致病作用的生物学治疗方法,本研究用获得的高纯度的人CRP蛋白对体外培养的缺氧状态下的乳大鼠心肌细胞进行干预,确定信号通路中重要蛋白,作为治疗靶点进行干预研究;从稳定分泌CRP单克隆抗体的杂交瘤细胞中克隆出抗体可变区,VH、VL通过Linker连接形成单链抗体,通过大肠杆菌表达后进行纯化,初步探讨CRP单链抗体对CRP致心肌细胞损伤的保护作用。
内容与方法:
1.采用Immobilized p-Aminophenyl phosphoryl Cholnie Gel亲和层析柱从感染、炎症期及肿瘤患者胸水中分离、纯化CRP,用质谱鉴定其成分,并通过SDS-PAGE与western blot检测其纯度与特异性。
2.从经TNF-alpha刺激的肝癌细胞系HepG2中,通过RT-PCR的方法,克隆人C-反应蛋白基因,并分别构建原核和真核表达载体,对原核表达载体进行了诱导表达和纯化,真核载体(pEGFP-N1-CRP)脂质体介导转染HEK293T细胞,荧光显微镜观察及western印迹法鉴定目的蛋白的表达。
3.克隆大鼠Bcl-2 cDNA序列,构建真核表达载体(pEGFP-N1-Bcl2)(Bcl-2 cDNA中含终止密码子TGC)。分离乳大鼠心肌细胞,空载体pEGFP-N1和pEGFP-N1-Bcl2脂质体介导转染培养分离的心肌细胞,荧光显微镜观察及Western blot鉴定目的蛋白的表达。
4.观察CRP干预对体外培养的乳大鼠心肌细胞的影响
(1)实验分为三组:
A.未转染组;B.pEGFP-N1转染组;C.pEGFP-N1-Bcl-2转染组。各组转染后48h,分别进行缺氧、100μg/ml CRP及缺氧+100μg/ml CRP干预;对照组为DMEM+10%FCS,正常氧含量、5%CO_2,37℃环境下培养。各组实验至少重复三次。
(2)Hochest 33258检测各组细胞凋亡情况。
(3)激光共聚焦免疫荧光定位和Western blot法分析细胞色素C在各组细胞中的分布,探讨细胞色素C的改变情况及其意义。
(4)RT-PCR和western blot分析各组细胞中Bax,Bcl-2的表达以及Bax/Bci-2的比值。用Caspase活性测定试剂盒分析各组细胞中Caspase-3,Caspase-9的活性。
5.从稳定分泌CRP单抗的杂交瘤中克隆出CRP-McAb可变区序列,通过Linker体外装配CRP单链抗体,构建原核、真核表达载体。对原核表达载体pET-28a-scFv诱导表达,包涵体蛋白经变性、复性,镍柱纯化,并通过SDS-PAGE与western blot进行鉴定。真核表达载体pEGFP-N1-scFv脂质体介导转染HEK293T细胞,荧光显微镜观察转染情况及western印迹法鉴定目的蛋白的表达。细胞免疫组化检测转染细胞表达的scFv对CRP的识别能力。
6.观察CRP-scFv对CRP所致乳大鼠心肌细胞损伤的影响,初步探讨scFv对损伤乳大鼠心肌细胞保护作用。
7.统计学方法:数据均测量数据以平均数加标准差((?)±s)表示。组间差异采用独立样本t检验、单因素方差分析和x~2检验(SPSS 13.0),P＜0.05有统计学意义。
结果
1.采用亲和层析法从肿瘤患者腹水中成功纯化出大小为24KD蛋白,SDS-PAGE检测纯度超过95%,用anti-CRP抗体进行western blot检测未见杂带,质谱鉴定表明所得蛋白为人C-反应蛋白。
2.成功克隆出人C-反应蛋白全长cDNA序列,测序证实与Genebank标准序列完全符合,并成功克隆至pET-28a和pEGFP-N1载体中。原核表达载体经1mM IPTG诱导表达后,SDS-PAGE检测在30KD处有一亮带,经western blot证实此条带为His-CRP融合蛋白。经镍柱亲和层析获得纯化的重组CRP蛋白。脂质体介导重组质粒pEGFP-N1-CRP转染HEK293T细胞,荧光显微镜观察及western印迹法均证实有目的蛋白表达。
3.成功克隆出大鼠Bcl-2全长cDNA序列,测序证实与Genebank标准序列完全符合,并成功克隆至pEGFP-N1载体中。成功通过M-PEI介导成功将重组pEGFP-N1-Bcl-2转染至分离培养的乳大鼠心肌细胞中,并通过western印迹法证实有目的蛋白表达。
4.CRP加重缺氧心肌细胞的凋亡。心肌细胞缺氧8h后凋亡率较对照组显著增加(P＜0.001),缺氧同时用100μg/ml CRP进行干预,细胞凋亡率比单独进行缺氧干预有显著性增加(P＜0.05)。
5.CRP加重缺氧心肌细胞线粒体中细胞色素C外流。细胞免疫荧光显示,对照组细胞中细胞色素C分布于线粒体中,缺氧8h细胞组中有少量细胞色素C发生移位,从线粒体转移至胞浆中,但当同时用缺氧和100μg/ml CRP进行干预时,细胞胞浆中弥散有大量细胞色素C。分别提取各组细胞线粒体和胞浆蛋白,用western blot分析进一步得到了证实。
6.RT-PCR和western blot检测显示CRP显著升高缺氧心肌细胞线粒体膜蛋白Bax/Bcl-2的比值。
7.CRP加重缺氧心肌细胞Caspase-9,Caspase-3的激活。单独缺氧干预8h,Caspase-9和Caspase-3活性与对照组相比均显著升高(P＜0.05)。缺氧和CRP同时干预组Caspase-9和Caspase-3活性与单独缺氧组相比显著升高(P＜0.05),但单独CRP干预后,Caspase-9和Caspase-3活性与对照组相比无显著性差异(P＞0.05)。
8.转染pEGFP-N1-Bcl-2后48h,DMEM培养基条件下,缺氧同时用100μg/ml CRP干预8h后心肌细胞比未转染细胞缺氧8h后凋亡率显著降低(P＜0.05)。在缺氧或同时用CRP干预条件下,过量表达Bcl-2蛋白不抑制细胞内Bax转录和表达水平,但Bax/Bcl-2比值比同样干预条件下的未转染组有显著下降。Bcl-2蛋白过表达抑制细胞色素C从线粒体向胞浆转移,进而抑制Caspase-9和Caspase-3活化。
9.成功从稳定分泌CRP单抗的杂交瘤中克隆出CRP-McAb可变区序列,测序后与V-Base数据库比对,确定阅读框,重叠延伸(overlap extend PCR)PCR将VH和VL通过Linker连接,并成功克隆入pET-28a和pEGFP-N1载体中。原核表达载体经1mM IPTG诱导表达后,SDS-PAGE检测在30KD处有一亮带,经western blot证实此条带为His-scFv融合蛋白。经镍柱亲和层析获得纯化的重组scFv蛋白。脂质体介导重组pEGFP-N1-scFv转染HEK293T细胞,荧光显微镜观察,western印迹法均证实有目的蛋白表达。细胞免疫组化结果证明表达的scFv可识别人CRP蛋白。
10.凋亡检测初步结果表明anti-CRP单克隆抗体(4E8C6H6F12E7D11)和重组scFv蛋白可抑制CRP诱导的缺氧心肌细胞的凋亡。
结论与讨论:
1.本研究中采用Immobilized p-Aminophenyl phosphoryl CholnieGel亲和层析柱从感染、炎症期及肿瘤患者胸水中分离、纯化CRP,此法得到的CRP纯度高,无NaN3污染,符合体外干预实验要求。
2.CRP加重缺氧诱导的乳大鼠心肌细胞的损伤,而对体外正常培养心肌细胞无影响。该结果与Pepys MB等在大鼠心肌梗塞模型中注射人类CRP后,出现梗死面积增加的现象相一致。表明体外培养心肌细胞进行缺氧+CRP处理是可用的细胞水平实验模型。
3.本研究发现心肌细胞线粒体膜蛋白Bax/Bcl-2的比值降低,导致线粒体膜通透性发生改变,细胞色素C从线粒体向胞浆转移,活化了Caspase-9和Caspaes-3可能是CRP加重缺氧诱导的乳大鼠心肌细胞凋亡的重要途径。过量表达Bcl-2蛋白后,CRP促凋亡作用被抑制,提示Bcl-2是该信号通路中重要蛋白,可作为靶点进行干预治疗。但在该通路上游,CRP是如何作用于损伤心肌细胞,还有待进一步深入研究。
4.本研究中从稳定分泌CRP单抗的杂交瘤中克隆出CRP-McAb可变区序列,经过表达、纯化获得了针对CRP的单链抗体,初步研究结果表明该重组单链抗体可抑制CRP诱导的缺氧心肌细胞的凋亡,为运用基因工程抗体作为生物技术药物针对CRP进行治疗提供了理论基础。
Background:C-reactive protein(CRP)is an acute-phase reactant,which belongs to the highly conserved pentraxin family of plasma proteins and serves as a pattern-recognition molecule in the innate immune system. Myocardial necrosis following acute myocardial infarction is a potent acute-phase stimulus;there is a major CRP response.Furthermore,there is considerable clinical considence supporting a strong association between the peak CRP values in circulating blood after the onset and the outcome of myocardial infarction.What remains less clear is whether CRP acts simply as a marker of vascular disease burden and activity or indeed participates in the development,progression,and complications of cardiovascular disease.In past few years,an increasing number of in vitro studies have indicated that CRP had exerting adverse and ultimately harmful effects on vascular smooth muscle cells(VSMCs),aortic endothelial cells,and therefore acts as a potential initiator and mediator of atherosclerosis.CRP was also found in the area of acute myocardial infarction,and showed positive correlation between the level of CRP and the infarct size.Furthermore,recently,therapeutic inhibition of CRP has been showed a promising new approach to cardio-protection in acute myocardial infarction in rat models.These results indicate that CRP may play an important role in the progression of cardiac dysfunction.Previous studies have confirmed that cytochrome C releasing from mitochondria then activates Caspase signal pathway may played important role in the cardiac apoptosis,but whether the key proteins mentioned above take part in the progress of CRP induced cardiac damage is little known.So,it is important to illustrate the molecular mechanism involved in the effects of CRP on the myocardial infarction and the cardiac-disorder,and it is a perspective work to explore a new atoxic drug with higher efficiency.
Objective:To investigate the direct effects of CRP on the cardiac myocyte and the molecular mechanism involved,and to explore a new efficient biological therapy against CRP,in this study,we used the hypoxia stimulated primary neonatal rat cardiac myocytes in vitro to simulate the cardiac myocyte in myocardial infarction in vivo.Within this system,we detected the effects of CRP on cardiac myocyte and look for the key point protein in the signal transduction pathway for intervention as the therapeutic target;the sequence of variable region was cloned from mouse hybridoma cells stably secreting anti-CRP antibody,the VH and VL were conjuncted with linker.The protein of scFv was obtained in the E.Coli,and the effects of scFv on CRP induced cardiac damage were observed in vitro.
Materials and methods:
1.Human CRP was isolated from malignant ascites fluid using Immobilized p-Aminophenyl Phosphoryl Choline Gel.The malignant ascites fluid was obtained from cancer patients and the investigation conforms to the principles outlined in the Declaration of Helsinki for use of human tissue or subjects.Purified human CRP was assayed by SDS-PAGE,mass-spectrum and western-blot analysis.
2.The full length of human C-reactive protein gene was cloned from TNF-alpha induced hepatoma cell line(HepG2)by RT-PCR and subcloned into prokaryotic and eukaryotic expression vector plasmid, named as pET-28a-CRP and pEGFP-N1-CRP,respectively.His-CRP was induced to express and purified by Ni~(2+)affinity chromatography. After transfection pEGFP-N1-CRP into HEK293T cells,the expression of CRP was observed under fluorescence microscope,and confirmed by western blotting.
3.The full length of rat Bcl-2 gene was cloned into pEGFP-N1 plasmid and named as pEGFP-N1-Bcl-2(Stop codon TGC was contained in the cDNA of Bcl-2).After transfected into cultured neonatal cardiac myocytes using M-PEI,the expression of Bcl-2 was observed under fluorescence microscope,and confirmed by western blotting.
4.The effects of CRP on cultured neonatal cardiac myocytes in virto were observed.
(1)Myocytes were divided into three groups:
A.None transfected myocytes;
B.pEGFP-N1 transfected myocytes;
C.pEGFP-N1-Bcl-2 transfected myocytes.
48 hours after transfection,myocytes were treated with 100μg/ml CRP,hypoxia and cotreatment with them respectively. Control myocytes were incubated in DMEM containing 10%FBS under normoxia.A hypoxic condition was created by incubating the cells with serum-free DMEM in an airtight Plexiglas chamber with an atmosphere of 5%CO_2/95%N_2 at 37℃for 8h in experiment.
(2)Determination of myocyte apoptosis was performed using cell apoptosis assay Kit(Hoechst 33258).
(3)The localization of Cyt c was detected with immunofluorescent under confocal microscope and the quantity of translocation of cytochrome c from mitochondria to cytolist was analyzed by western blot.
(4)The expressions of Bax and Bcl-2 and the ratio of Bax/Bcl-2 were analyzed by RT-PCR and western blot.Caspase-9 and Caspase-3 activities were determined with a Caspase assay kit.
5.CRP-McAb variable region(VH and VL)was cloned from mouse hybridoma cells stably secreting anti-CRP antibody,the VH and VL were conjuncted with Linker.The prokaryotic and eukaryotic expression vector were constructed,His-scFv was induced to expression existed majorly in the inclusion body,after denaturation and renaturation,the protein was purified by Ni~(2+)affinity chromatography and detected by SDS-PAGE and western blot.The plasmid pEGFP-N1-scFv was transfected into HEK293T cells using M-PEI,the expression of scFv was observed under fluorescence microscope and confirmed by western blotting.Cellular immunostaining was used to detect the ability of recognization between expressed scFv and human CRP.
6.The anti-apoptosis effect of CRP-scFv was analyzed with in situ apoptosis detection kit—TUNEL.
7.Statistics:The data mentioned above at least derived from three independent experiments.All data are presented as mean±SD.The independent samples T test,one way ANOVA and chi-square test were used to analyze differences and statistical tests were performed with the use of SPSS 13.0 statistical software.Statistical significance was accepted at P＜0.05.
Results:
1.CRP purified from malignant ascites fluid using Immobilized p-Aminophenyl Phosphoryl Choline Gel was in the monomeric form (24KD)with no detection of other proteins by silver staining on SDS-PAGE(purity up to 95%),western-blot or mass-spectrum.
2.The full length cDNA of human CRP was successfully cloned,DNA sequencing and BLAST algorithm revealed that the cDNA was exactly identical to the reported sequence in the Genebank.The CRP gene was then successfully subcloned into pET-28a and pEGFP-N1. After induction with 1mM IPTG at 37℃for 4h,E.coli BL21(DE3) transformed with pET28a-CRP produced a fusion protein of approximately 30 kDa,which matched well with the theoretical molecular weight of His-CRP.The expressed recombinant CRP was purified by Ni~(2+)affinity chromatography and detected by anti-CRP antibody.The plasmid pEGFP-N1-Bcl-2 was successfully transfected into HEK293T cells using M-PEI which resulted in significant increased CRP protein expression.
3.The full length cDNA of rat Bcl-2 was successfully cloned,DNA sequencing and BLAST algorithm revealed that the cDNA was exactly identical to the reported sequence in the Genebank.The Bcl-2 gene was then successfully subcloned into pEGFP-N1.Cultured neonatal cardiac myocytes transfected using M-PEI which resulted in 70%to 80%transfection efficiency and significant increase in Bcl-2 protein expression.
4.CRP augmented hypoxia-induced cell apoptosis.The percentage of apoptotic myocytes increased significantly after 8 hours hypoxia,as compared with control.Cotreatment of hypoxia with CRP(100μg/mL) significantly increased the percentage of apoptotic cells.However, CRP did not induce myocytes apoptosis significantly under normoxia.
5.CRP induced more cytochrome c release than hypoxia alone.Control cardiac myocyte demonstrated organized speckled patterns of cytochrome c that colocalized with mitochondria.In contrast,after hypoxia for 8 hours,there was little cytochrome c in cytolist but after cotreatment with hypoxia and 100μg/mL CRP,cytochrome c staining diffused throughout the cells,no longer colocalized to the mitochondria.The phenomenon was further conformed by western blot which detected the quantity of translocation of cytochrome c from mitochondria to cytolist.
6.CRP increased the ratio of Bax/Bcl-2 in the hypoxia-induced cardiac myocyte.
7.CRP further increased the hypoxia-induced activation of Caspase-9 and Caspase-3 significantly.However CRP showed no action on the activity Caspase-9 and Caspase-3 during normoxia.
8.Bcl-2 over-expression in cultured neonatal cardiomyocytes resulted in significant inhibition of cotreatment of hypoxia with CRP-induced apoptosis,cytochrome c release,Bax/Bcl-2 ratio increase and Caspases activation.
9.The cDNA of CRP-McAb variable region(VH and VL)was successfully cloned from mouse hybridoma cells stably secreting anti-CRP antibody.After DNA sequencing and read frame definition according to the V-base,the VH and VL were conjuncted with Linker using overlapping extension PCR.The scFv gene was successfully subcloned into pET-28a and pEGFP-N1.After induction with 1mM IPTG,a fusion protein of approximately 30 kDa was produced,which matched well with the theoretical molecular weight of His-scFv.The expressed recombinant scFv was purified by Ni~(2+)affinity chromatography and detected by anti-His antibody.The plasmid pEGFP-N1-scFv was successfully transfected into HEK293T cells using M-PEI which resulted in significant increasing of scFv expression.Cellular immunostaining showed that the expressed scFv could be recognized by human CRP.
10.Our preliminary data of myocyte apoptosis analysis indicated that anti-CRP antibody(4E8C6H6F12E7D11)and recombinant scFv protein could inhibit cardiac myocyte apoptosis induced by hypoxia cotreated with CRP.
Discussion and conclusion:
1.A number of recent studies have used commercial CRP preparations that remain poorly characterized and indeed contain known quantities of biologically active contaminants such as sodium azide.So,in this study,we used affinity chromatography(Immobilized p-Aminophenyl Phosphoryl Choline Gel)to purify human C-reactive protein from malignant ascites fluid of the patients.Our purified CRP is of high purity,without Na_3N contamination,and is suitable for the in vitro intervention.
2.The data of this study suggest a potential mechanism that CRP could enhance apoptosis in hypoxia-stimulated neonatal rat cardiac myocytes through the mitochondrion-dependent pathway but CRP alone has no effects on neonatal rat cardiac myocytes under normoxia, which is consist with the results of Pepys MB's group that injection of human CRP to rats undergoing acute myocardial infarction increased infarct size and aggravated cardiac dysfunction.
3.The present study demonstrates for the first time CRP can regulate the Bax and Bcl-2 proteins in mitochondria and decrease the ratio of Bax/Bcl-2,augment mitochondrial death pathway through provoking the mitochondrial permeability transition,therefore cytochrome c released from the mitochondria to the cytosol,activate Caspase-9 and Caspase-3 in hypoxic cardiac myocytes,a fact which indicate that therapeutic inhibition of CRP may have significant implications in the development of future therapies to combat the effects of myocardial infarction.But,further studies are needed to clarify the upstream signal pathway of the pro-apoptotic action of CRP and the receptor of CRP in the cell membrane.
4.In this study,we cloned cDNA of CRP-McAb variable region(VH and VL)from mouse hybridoma cells stably secreting anti-CRP antibody and obtained scFv antibody against CRP after expression and purification.Our preliminary study suggested that recombinant scFv protein could inhibit inhibit cardiac myocyte apoptosis induced by hypoxia cotreated with CRP.These results provide exciting future for using genetically engineered antibody to biological therapy against CRP.
目的:为探讨CRP对心肌细胞的直接损伤作用和分子机制,寻找一种阻断CRP致病作用的生物学治疗方法,本研究用获得的高纯度的人CRP蛋白对体外培养的缺氧状态下的乳大鼠心肌细胞进行干预,确定信号通路中重要蛋白,作为治疗靶点进行干预研究;从稳定分泌CRP单克隆抗体的杂交瘤细胞中克隆出抗体可变区,VH、VL通过Linker连接形成单链抗体,通过大肠杆菌表达后进行纯化,初步探讨CRP单链抗体对CRP致心肌细胞损伤的保护作用。
内容与方法:
1.采用Immobilized p-Aminophenyl phosphoryl Cholnie Gel亲和层析柱从感染、炎症期及肿瘤患者胸水中分离、纯化CRP,用质谱鉴定其成分,并通过SDS-PAGE与western blot检测其纯度与特异性。
2.从经TNF-alpha刺激的肝癌细胞系HepG2中,通过RT-PCR的方法,克隆人C-反应蛋白基因,并分别构建原核和真核表达载体,对原核表达载体进行了诱导表达和纯化,真核载体(pEGFP-N1-CRP)脂质体介导转染HEK293T细胞,荧光显微镜观察及western印迹法鉴定目的蛋白的表达。
3.克隆大鼠Bcl-2 cDNA序列,构建真核表达载体(pEGFP-N1-Bcl2)(Bcl-2 cDNA中含终止密码子TGC)。分离乳大鼠心肌细胞,空载体pEGFP-N1和pEGFP-N1-Bcl2脂质体介导转染培养分离的心肌细胞,荧光显微镜观察及Western blot鉴定目的蛋白的表达。
4.观察CRP干预对体外培养的乳大鼠心肌细胞的影响
(1)实验分为三组:
A.未转染组;B.pEGFP-N1转染组;C.pEGFP-N1-Bcl-2转染组。各组转染后48h,分别进行缺氧、100μg/ml CRP及缺氧+100μg/ml CRP干预;对照组为DMEM+10%FCS,正常氧含量、5%CO_2,37℃环境下培养。各组实验至少重复三次。
(2)Hochest 33258检测各组细胞凋亡情况。
(3)激光共聚焦免疫荧光定位和Western blot法分析细胞色素C在各组细胞中的分布,探讨细胞色素C的改变情况及其意义。
(4)RT-PCR和western blot分析各组细胞中Bax,Bcl-2的表达以及Bax/Bci-2的比值。用Caspase活性测定试剂盒分析各组细胞中Caspase-3,Caspase-9的活性。
5.从稳定分泌CRP单抗的杂交瘤中克隆出CRP-McAb可变区序列,通过Linker体外装配CRP单链抗体,构建原核、真核表达载体。对原核表达载体pET-28a-scFv诱导表达,包涵体蛋白经变性、复性,镍柱纯化,并通过SDS-PAGE与western blot进行鉴定。真核表达载体pEGFP-N1-scFv脂质体介导转染HEK293T细胞,荧光显微镜观察转染情况及western印迹法鉴定目的蛋白的表达。细胞免疫组化检测转染细胞表达的scFv对CRP的识别能力。
6.观察CRP-scFv对CRP所致乳大鼠心肌细胞损伤的影响,初步探讨scFv对损伤乳大鼠心肌细胞保护作用。
7.统计学方法:数据均测量数据以平均数加标准差((?)±s)表示。组间差异采用独立样本t检验、单因素方差分析和x~2检验(SPSS 13.0),P＜0.05有统计学意义。
结果
1.采用亲和层析法从肿瘤患者腹水中成功纯化出大小为24KD蛋白,SDS-PAGE检测纯度超过95%,用anti-CRP抗体进行western blot检测未见杂带,质谱鉴定表明所得蛋白为人C-反应蛋白。
2.成功克隆出人C-反应蛋白全长cDNA序列,测序证实与Genebank标准序列完全符合,并成功克隆至pET-28a和pEGFP-N1载体中。原核表达载体经1mM IPTG诱导表达后,SDS-PAGE检测在30KD处有一亮带,经western blot证实此条带为His-CRP融合蛋白。经镍柱亲和层析获得纯化的重组CRP蛋白。脂质体介导重组质粒pEGFP-N1-CRP转染HEK293T细胞,荧光显微镜观察及western印迹法均证实有目的蛋白表达。
3.成功克隆出大鼠Bcl-2全长cDNA序列,测序证实与Genebank标准序列完全符合,并成功克隆至pEGFP-N1载体中。成功通过M-PEI介导成功将重组pEGFP-N1-Bcl-2转染至分离培养的乳大鼠心肌细胞中,并通过western印迹法证实有目的蛋白表达。
4.CRP加重缺氧心肌细胞的凋亡。心肌细胞缺氧8h后凋亡率较对照组显著增加(P＜0.001),缺氧同时用100μg/ml CRP进行干预,细胞凋亡率比单独进行缺氧干预有显著性增加(P＜0.05)。
5.CRP加重缺氧心肌细胞线粒体中细胞色素C外流。细胞免疫荧光显示,对照组细胞中细胞色素C分布于线粒体中,缺氧8h细胞组中有少量细胞色素C发生移位,从线粒体转移至胞浆中,但当同时用缺氧和100μg/ml CRP进行干预时,细胞胞浆中弥散有大量细胞色素C。分别提取各组细胞线粒体和胞浆蛋白,用western blot分析进一步得到了证实。
6.RT-PCR和western blot检测显示CRP显著升高缺氧心肌细胞线粒体膜蛋白Bax/Bcl-2的比值。
7.CRP加重缺氧心肌细胞Caspase-9,Caspase-3的激活。单独缺氧干预8h,Caspase-9和Caspase-3活性与对照组相比均显著升高(P＜0.05)。缺氧和CRP同时干预组Caspase-9和Caspase-3活性与单独缺氧组相比显著升高(P＜0.05),但单独CRP干预后,Caspase-9和Caspase-3活性与对照组相比无显著性差异(P＞0.05)。
8.转染pEGFP-N1-Bcl-2后48h,DMEM培养基条件下,缺氧同时用100μg/ml CRP干预8h后心肌细胞比未转染细胞缺氧8h后凋亡率显著降低(P＜0.05)。在缺氧或同时用CRP干预条件下,过量表达Bcl-2蛋白不抑制细胞内Bax转录和表达水平,但Bax/Bcl-2比值比同样干预条件下的未转染组有显著下降。Bcl-2蛋白过表达抑制细胞色素C从线粒体向胞浆转移,进而抑制Caspase-9和Caspase-3活化。
9.成功从稳定分泌CRP单抗的杂交瘤中克隆出CRP-McAb可变区序列,测序后与V-Base数据库比对,确定阅读框,重叠延伸(overlap extend PCR)PCR将VH和VL通过Linker连接,并成功克隆入pET-28a和pEGFP-N1载体中。原核表达载体经1mM IPTG诱导表达后,SDS-PAGE检测在30KD处有一亮带,经western blot证实此条带为His-scFv融合蛋白。经镍柱亲和层析获得纯化的重组scFv蛋白。脂质体介导重组pEGFP-N1-scFv转染HEK293T细胞,荧光显微镜观察,western印迹法均证实有目的蛋白表达。细胞免疫组化结果证明表达的scFv可识别人CRP蛋白。
10.凋亡检测初步结果表明anti-CRP单克隆抗体(4E8C6H6F12E7D11)和重组scFv蛋白可抑制CRP诱导的缺氧心肌细胞的凋亡。
结论与讨论:
1.本研究中采用Immobilized p-Aminophenyl phosphoryl CholnieGel亲和层析柱从感染、炎症期及肿瘤患者胸水中分离、纯化CRP,此法得到的CRP纯度高,无NaN3污染,符合体外干预实验要求。
2.CRP加重缺氧诱导的乳大鼠心肌细胞的损伤,而对体外正常培养心肌细胞无影响。该结果与Pepys MB等在大鼠心肌梗塞模型中注射人类CRP后,出现梗死面积增加的现象相一致。表明体外培养心肌细胞进行缺氧+CRP处理是可用的细胞水平实验模型。
3.本研究发现心肌细胞线粒体膜蛋白Bax/Bcl-2的比值降低,导致线粒体膜通透性发生改变,细胞色素C从线粒体向胞浆转移,活化了Caspase-9和Caspaes-3可能是CRP加重缺氧诱导的乳大鼠心肌细胞凋亡的重要途径。过量表达Bcl-2蛋白后,CRP促凋亡作用被抑制,提示Bcl-2是该信号通路中重要蛋白,可作为靶点进行干预治疗。但在该通路上游,CRP是如何作用于损伤心肌细胞,还有待进一步深入研究。
4.本研究中从稳定分泌CRP单抗的杂交瘤中克隆出CRP-McAb可变区序列,经过表达、纯化获得了针对CRP的单链抗体,初步研究结果表明该重组单链抗体可抑制CRP诱导的缺氧心肌细胞的凋亡,为运用基因工程抗体作为生物技术药物针对CRP进行治疗提供了理论基础。
Background:C-reactive protein(CRP)is an acute-phase reactant,which belongs to the highly conserved pentraxin family of plasma proteins and serves as a pattern-recognition molecule in the innate immune system. Myocardial necrosis following acute myocardial infarction is a potent acute-phase stimulus;there is a major CRP response.Furthermore,there is considerable clinical considence supporting a strong association between the peak CRP values in circulating blood after the onset and the outcome of myocardial infarction.What remains less clear is whether CRP acts simply as a marker of vascular disease burden and activity or indeed participates in the development,progression,and complications of cardiovascular disease.In past few years,an increasing number of in vitro studies have indicated that CRP had exerting adverse and ultimately harmful effects on vascular smooth muscle cells(VSMCs),aortic endothelial cells,and therefore acts as a potential initiator and mediator of atherosclerosis.CRP was also found in the area of acute myocardial infarction,and showed positive correlation between the level of CRP and the infarct size.Furthermore,recently,therapeutic inhibition of CRP has been showed a promising new approach to cardio-protection in acute myocardial infarction in rat models.These results indicate that CRP may play an important role in the progression of cardiac dysfunction.Previous studies have confirmed that cytochrome C releasing from mitochondria then activates Caspase signal pathway may played important role in the cardiac apoptosis,but whether the key proteins mentioned above take part in the progress of CRP induced cardiac damage is little known.So,it is important to illustrate the molecular mechanism involved in the effects of CRP on the myocardial infarction and the cardiac-disorder,and it is a perspective work to explore a new atoxic drug with higher efficiency.
Objective:To investigate the direct effects of CRP on the cardiac myocyte and the molecular mechanism involved,and to explore a new efficient biological therapy against CRP,in this study,we used the hypoxia stimulated primary neonatal rat cardiac myocytes in vitro to simulate the cardiac myocyte in myocardial infarction in vivo.Within this system,we detected the effects of CRP on cardiac myocyte and look for the key point protein in the signal transduction pathway for intervention as the therapeutic target;the sequence of variable region was cloned from mouse hybridoma cells stably secreting anti-CRP antibody,the VH and VL were conjuncted with linker.The protein of scFv was obtained in the E.Coli,and the effects of scFv on CRP induced cardiac damage were observed in vitro.
Materials and methods:
1.Human CRP was isolated from malignant ascites fluid using Immobilized p-Aminophenyl Phosphoryl Choline Gel.The malignant ascites fluid was obtained from cancer patients and the investigation conforms to the principles outlined in the Declaration of Helsinki for use of human tissue or subjects.Purified human CRP was assayed by SDS-PAGE,mass-spectrum and western-blot analysis.
2.The full length of human C-reactive protein gene was cloned from TNF-alpha induced hepatoma cell line(HepG2)by RT-PCR and subcloned into prokaryotic and eukaryotic expression vector plasmid, named as pET-28a-CRP and pEGFP-N1-CRP,respectively.His-CRP was induced to express and purified by Ni~(2+)affinity chromatography. After transfection pEGFP-N1-CRP into HEK293T cells,the expression of CRP was observed under fluorescence microscope,and confirmed by western blotting.
3.The full length of rat Bcl-2 gene was cloned into pEGFP-N1 plasmid and named as pEGFP-N1-Bcl-2(Stop codon TGC was contained in the cDNA of Bcl-2).After transfected into cultured neonatal cardiac myocytes using M-PEI,the expression of Bcl-2 was observed under fluorescence microscope,and confirmed by western blotting.
4.The effects of CRP on cultured neonatal cardiac myocytes in virto were observed.
(1)Myocytes were divided into three groups:
A.None transfected myocytes;
B.pEGFP-N1 transfected myocytes;
C.pEGFP-N1-Bcl-2 transfected myocytes.
48 hours after transfection,myocytes were treated with 100μg/ml CRP,hypoxia and cotreatment with them respectively. Control myocytes were incubated in DMEM containing 10%FBS under normoxia.A hypoxic condition was created by incubating the cells with serum-free DMEM in an airtight Plexiglas chamber with an atmosphere of 5%CO_2/95%N_2 at 37℃for 8h in experiment.
(2)Determination of myocyte apoptosis was performed using cell apoptosis assay Kit(Hoechst 33258).
(3)The localization of Cyt c was detected with immunofluorescent under confocal microscope and the quantity of translocation of cytochrome c from mitochondria to cytolist was analyzed by western blot.
(4)The expressions of Bax and Bcl-2 and the ratio of Bax/Bcl-2 were analyzed by RT-PCR and western blot.Caspase-9 and Caspase-3 activities were determined with a Caspase assay kit.
5.CRP-McAb variable region(VH and VL)was cloned from mouse hybridoma cells stably secreting anti-CRP antibody,the VH and VL were conjuncted with Linker.The prokaryotic and eukaryotic expression vector were constructed,His-scFv was induced to expression existed majorly in the inclusion body,after denaturation and renaturation,the protein was purified by Ni~(2+)affinity chromatography and detected by SDS-PAGE and western blot.The plasmid pEGFP-N1-scFv was transfected into HEK293T cells using M-PEI,the expression of scFv was observed under fluorescence microscope and confirmed by western blotting.Cellular immunostaining was used to detect the ability of recognization between expressed scFv and human CRP.
6.The anti-apoptosis effect of CRP-scFv was analyzed with in situ apoptosis detection kit—TUNEL.
7.Statistics:The data mentioned above at least derived from three independent experiments.All data are presented as mean±SD.The independent samples T test,one way ANOVA and chi-square test were used to analyze differences and statistical tests were performed with the use of SPSS 13.0 statistical software.Statistical significance was accepted at P＜0.05.
Results:
1.CRP purified from malignant ascites fluid using Immobilized p-Aminophenyl Phosphoryl Choline Gel was in the monomeric form (24KD)with no detection of other proteins by silver staining on SDS-PAGE(purity up to 95%),western-blot or mass-spectrum.
2.The full length cDNA of human CRP was successfully cloned,DNA sequencing and BLAST algorithm revealed that the cDNA was exactly identical to the reported sequence in the Genebank.The CRP gene was then successfully subcloned into pET-28a and pEGFP-N1. After induction with 1mM IPTG at 37℃for 4h,E.coli BL21(DE3) transformed with pET28a-CRP produced a fusion protein of approximately 30 kDa,which matched well with the theoretical molecular weight of His-CRP.The expressed recombinant CRP was purified by Ni~(2+)affinity chromatography and detected by anti-CRP antibody.The plasmid pEGFP-N1-Bcl-2 was successfully transfected into HEK293T cells using M-PEI which resulted in significant increased CRP protein expression.
3.The full length cDNA of rat Bcl-2 was successfully cloned,DNA sequencing and BLAST algorithm revealed that the cDNA was exactly identical to the reported sequence in the Genebank.The Bcl-2 gene was then successfully subcloned into pEGFP-N1.Cultured neonatal cardiac myocytes transfected using M-PEI which resulted in 70%to 80%transfection efficiency and significant increase in Bcl-2 protein expression.
4.CRP augmented hypoxia-induced cell apoptosis.The percentage of apoptotic myocytes increased significantly after 8 hours hypoxia,as compared with control.Cotreatment of hypoxia with CRP(100μg/mL) significantly increased the percentage of apoptotic cells.However, CRP did not induce myocytes apoptosis significantly under normoxia.
5.CRP induced more cytochrome c release than hypoxia alone.Control cardiac myocyte demonstrated organized speckled patterns of cytochrome c that colocalized with mitochondria.In contrast,after hypoxia for 8 hours,there was little cytochrome c in cytolist but after cotreatment with hypoxia and 100μg/mL CRP,cytochrome c staining diffused throughout the cells,no longer colocalized to the mitochondria.The phenomenon was further conformed by western blot which detected the quantity of translocation of cytochrome c from mitochondria to cytolist.
6.CRP increased the ratio of Bax/Bcl-2 in the hypoxia-induced cardiac myocyte.
7.CRP further increased the hypoxia-induced activation of Caspase-9 and Caspase-3 significantly.However CRP showed no action on the activity Caspase-9 and Caspase-3 during normoxia.
8.Bcl-2 over-expression in cultured neonatal cardiomyocytes resulted in significant inhibition of cotreatment of hypoxia with CRP-induced apoptosis,cytochrome c release,Bax/Bcl-2 ratio increase and Caspases activation.
9.The cDNA of CRP-McAb variable region(VH and VL)was successfully cloned from mouse hybridoma cells stably secreting anti-CRP antibody.After DNA sequencing and read frame definition according to the V-base,the VH and VL were conjuncted with Linker using overlapping extension PCR.The scFv gene was successfully subcloned into pET-28a and pEGFP-N1.After induction with 1mM IPTG,a fusion protein of approximately 30 kDa was produced,which matched well with the theoretical molecular weight of His-scFv.The expressed recombinant scFv was purified by Ni~(2+)affinity chromatography and detected by anti-His antibody.The plasmid pEGFP-N1-scFv was successfully transfected into HEK293T cells using M-PEI which resulted in significant increasing of scFv expression.Cellular immunostaining showed that the expressed scFv could be recognized by human CRP.
10.Our preliminary data of myocyte apoptosis analysis indicated that anti-CRP antibody(4E8C6H6F12E7D11)and recombinant scFv protein could inhibit cardiac myocyte apoptosis induced by hypoxia cotreated with CRP.
Discussion and conclusion:
1.A number of recent studies have used commercial CRP preparations that remain poorly characterized and indeed contain known quantities of biologically active contaminants such as sodium azide.So,in this study,we used affinity chromatography(Immobilized p-Aminophenyl Phosphoryl Choline Gel)to purify human C-reactive protein from malignant ascites fluid of the patients.Our purified CRP is of high purity,without Na_3N contamination,and is suitable for the in vitro intervention.
2.The data of this study suggest a potential mechanism that CRP could enhance apoptosis in hypoxia-stimulated neonatal rat cardiac myocytes through the mitochondrion-dependent pathway but CRP alone has no effects on neonatal rat cardiac myocytes under normoxia, which is consist with the results of Pepys MB's group that injection of human CRP to rats undergoing acute myocardial infarction increased infarct size and aggravated cardiac dysfunction.
3.The present study demonstrates for the first time CRP can regulate the Bax and Bcl-2 proteins in mitochondria and decrease the ratio of Bax/Bcl-2,augment mitochondrial death pathway through provoking the mitochondrial permeability transition,therefore cytochrome c released from the mitochondria to the cytosol,activate Caspase-9 and Caspase-3 in hypoxic cardiac myocytes,a fact which indicate that therapeutic inhibition of CRP may have significant implications in the development of future therapies to combat the effects of myocardial infarction.But,further studies are needed to clarify the upstream signal pathway of the pro-apoptotic action of CRP and the receptor of CRP in the cell membrane.
4.In this study,we cloned cDNA of CRP-McAb variable region(VH and VL)from mouse hybridoma cells stably secreting anti-CRP antibody and obtained scFv antibody against CRP after expression and purification.Our preliminary study suggested that recombinant scFv protein could inhibit inhibit cardiac myocyte apoptosis induced by hypoxia cotreated with CRP.These results provide exciting future for using genetically engineered antibody to biological therapy against CRP.
引文
[1] Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
[2] Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108:2292-2297.
[3] Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
[4] Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005; 167:1139 -1148.
[5] Nilsson J. CRP: marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol. 2005;25:1527-1528.
[6] Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res. 2005;96:714-716.
[7] Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386 -1392.
[8] Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112:25-31.
[9] Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106:1439—1441.
[10]Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001 ;103: 2531-2534.
[11]Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;109:647- 655.
[12]Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res. 2005;96:714-716.
[13]Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005;167:923-925.
[14] Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
[15] Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352: 1646-1654.
[16]Nijmeijer R, Lagrand WK, Lubbers YT, Visser CA, Meijer CJ. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol. 2003;163(1):269-75.
[17]Baidoshvili A, Nijmeijer R, Lagrand WK, Hack CE. Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis. J Clin Pathol. 2002;55(2):152-3.
[18]Nijmeijer R, Lagrand WK, Visser CA. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int Immunopharmacol. 2001;1(3):403-14.
[19]Bian GX, Li GG, Yang Y, Liu RT, Ren JP. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008;31(3):458-63.
[20]Bellocci F, Biasucci LM, Gensini GF, Padeletti L, Raviele A. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study. J Cardiovasc Med (Hagerstown). 2007;8(4):293-9.
[21] Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab. 2004;24(11):1214-8.
[22]Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol. 2004;137(1):117-22.
[23]Valtchanova-Matchouganska A, Gondwe M, Nadar A. The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction. Life Sci. 2004;75(8):901-10.
[24] Mark B. Pepys, Gideon M. Hirschfield, Glenys A. Tennent, J. Ruth Gallimore, Melvyn C. Kahan, Vittorio Bellotti, Philip N. Hawkins, Rebecca M. Myers, Martin D. Smith, Alessandra Polara, Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006: 440: 1217-1222.
[25]Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest. 2008 Mar 6; [Epub ahead of print]
[26]Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. Bio Drugs. 2008;22(1):11-26.
[27]Mousli M, Turki I, Kharmachi H, Saadi M, Dellagi K.Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J Virol Methods. 2007;146(1-2):246-56.
[28]Baum P, Muller D, Ruger R, Kontermann RE. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target. 2007;15(6):399-406.
[29] Worn A, Pliickthun A. Stability engineering of antibody single-chain Fv fragments.J Mol Biol. 2001;305(5):989-1010.
[1] Black S, Kushner I, Samols D. C-reactive Protein. The Journal of biological chemistry 2004;279:48487-48490.
[2] Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-1566.
[3] Schwick HG, Haupt H. Properties of acute phase proteins of human plasma. Behring Institute Mitteilungen 1986:1-10.
[4] Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528-1536.
[5] Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology, gene expression, and host defense function. Immunologic research 1997;16:127-136.
[6] Ramadan MA, Shrive AK, Holden D, Myles DA, Volanakis JE, DeLucas LJ, et al. The three-dimensional structure of calcium-depleted human C-reactive protein from perfectly twinned crystals. Acta crystallographica 2002;58:992-1001.
[7] Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, et al. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006;48:504-511.
[8] Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999;37:265-270.
[9] Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England journal of medicine 2004;350:1387-1397.
[10]Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. Qjm 2003;96:793-807.
[11]Ikuta T, Okubo H, Ishibashi H, Okumura Y, Hayashida K. Human lymphocytes synthesize C-reactive protein. Inflammation 1986; 10:223-232.
[12]Szmitko PE, Verma S. C-reactive protein and statins: IL-8 as a molecular link? Clin Sci (Lond) 2005;108:493-495.
[13] Chun OK, Chung SJ, Claycombe KJ, Song WO. Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in u.s. Adults. The Journal of nutrition 2008;138:753-760.
[14]Kuji T, Masaki T, Li L, Cheung AK. Expression of C-reactive protein in myointimal hyperplasia in a porcine arteriovenous graft model. Nephrol Dial Transplant 2007;22:2469-2475.
[15]Makrides SC. Components of vectors for gene transfer and expression in mammalian cells. Protein expression and purification 1999; 17:183-202.
[16]Yi S, Brickenden A, Choy WY. A new protocol for high-yield purification of recombinant human prothymosin alpha expressed in Escherichia coli for NMR studies. Protein expression and purification 2008;57:1-8.
[17]Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY 1971;136:612-614.
[18]Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol 1981; 126:1820-1825.
[19]Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 1974;113:9-17.
[20]Ikuta T, Okubo H, Yukimura H, Ishibashi H. Purification of C-reactive protein. Biochemistry international 1983;6:275-282.
[21]Volanakis JE, Wirtz KW. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 1979;281:155-157.
[22] Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109:2058-2067.
[23]Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
[24] Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circulation research 2005;97:135-143.
[25] Swafford AN, Jr., Bratz IN, Knudson JD, Rogers PA, Timmerman JM, Tune JD, et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. American journal of physiology 2005;288:H1786-1795.
[26]Martensen TM. Phosphotyrosine in proteins. Stability and quantification. The Journal of biological chemistry 1982;257:9648-9652.
[27]Sahdev S, Khattar SK, Saini KS. Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Molecular and cellular biochemistry 2008;307:249-264.
[28] Cunningham F, Deber CM. Optimizing synthesis and expression of transmembrane peptides and proteins. Methods (San Diego, Calif 2007;41:370-380.
[29]Leder L, Freuler F, Forstner M, Mayr LM. New methods for efficient protein production in drug discovery. Current opinion in drug discovery & development 2007;10:193-202.
[1] Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2595-2599.
[2] Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
[3] Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England journal of medicine 1997;336:973-979.
[4] Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England journal of medicine 2000;342:836-843.
[5] Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama 2001;285:2481-2485.
[6] Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circulation research 2004;95:877-883.
[7] Suh W, Kim KL, Choi JH, Lee YS, Lee JY, Kim JM, et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochemical and biophysical research communications 2004;321:65-71.
[8] Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
[9] Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
[10] Wang Q, Zhu X, Xu Q, Ding X, Chen YE, Song Q. Effect of C-reactive protein on gene expression in vascular endothelial cells. American journal of physiology 2005;288:H1539-1545.
[11]Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. Journal of molecular and cellular cardiology 2004;36:405-410.
[12]Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
[13] Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low-density lipoprotein uptake and matrix metalloproteinase-9 release in wistar rats. Journal of lipid research 2008.
[14]Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovascular research 2003;58:186-195.
[15]Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
[16]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
[17] Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. American journal of physiology 2001 ;280:H2313-2320.
[18]Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (New York, NY 1984;226:1097-1099.
[19] Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-323.
[20]Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circulation research 2000;87:118-125.
[21]Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor- dependent monocyte recruitment in atherogenesis. Arteriosclerosis, thrombosis, and vascular biology 2000;20:2094-2099.
[22] Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical hypotheses 2004;62:499-506.
[23] Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996;348:567-572.
[24]Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-436.
[25]Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathology international 1995;45:635-641.
[26]Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
[27] Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. The Journal of experimental medicine 1999;190:1733-1740.
[28] Crow MT, Mani K, Nam YJ, Kitsis RN. The mitochondrial death pathway and cardiac myocyte apoptosis. Circulation research 2004;95:957-970.
[29] de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. British heart journal 1982;47:239-243.
[30]Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circulation research 2005;97:135-143.
[31] Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D, et al. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Molecular and cellular biochemistry 2008;310:215-226.
[32]Ikuta T, Okubo H, Ishibashi H, Okumura Y, Hayashida K. Human lymphocytes synthesize C-reactive protein. Inflammation 1986;10:223-232.
[33]Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-1932.
[34]Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110:579-587.
[35]Ikeda U, Maeda Y, Yamamoto K, Shimada K. C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovascular research 2002;56:86-92.
[36]Green DR, Reed JC. Mitochondria and apoptosis. Science (New York, NY 1998;281:1309-1312.
[37]Bialik S, Cryns VL, Drincic A, Miyata S, Wollowick AL, Srinivasan A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circulation research 1999;85:403-414.
[38]Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 1996;94:1506-1512.
[1] Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
[2] Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
[3] Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical hypotheses 2004;62:499-506.
[4] Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circulation research 2004;95:877-883.
[5] Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
[6] Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. The American journal of the medical sciences 2002;324:14-30.
[7] Benhar I, Pastan I. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin Cancer Res 1995;1:1023-1029.
[8] Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proceedings of the National Academy of Sciences of the United States of America 1991;88:8616-8620.
[9] Yang J, Moyana T, MacKenzie S, Xia Q, Xiang J. One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV/TNF-alpha) from Escherichia coli caused by the synergistic effects of glycine and triton X-100. Applied and environmental microbiology 1998;64:2869-2874.
[10]Verma R, Boleti E, George AJ. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. Journal of immunological methods 1998;216:165-181.
[11] Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer research 1992;52:6310-6317.
[12]Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer research 1992;52:3402-3408.
[13] Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989;341:544-546.
[14]DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Seminars in nuclear medicine 2005;35:143-151.
[15] Zhou J, Zhong Y. Breast cancer immunotherapy. Cellular & molecular immunology 2004;1 :247-255.
[16] Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Seminars in oncology 2004;31:196-205.
[17]Hust M, Dubel S. Phage display vectors for the in vitro generation of human antibody fragments. Methods in molecular biology (Clifton, NJ 2005;295:71-96.
[18]Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, Tayapiwatana C. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC biotechnology 2008;8:5.
[19] Tang YM, Ning BT, Cao J, Shen HQ, Qian BQ. Construction and expression of single-chain antibody derived from a new clone of monoclonal antibody against human CD14 in CHO cells. Immunopharmacology and immunotoxicology 2007;29:375-386.
[20] Liu M, Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, et al. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb. The Biochemical journal 2007;406: 237-246.
[21] Lee JJ, Chu E. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Clinical colorectal cancer 2007;7 Suppl 1:S16-20.
[22] Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer research 1993;53:1945-1951.
1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-54.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-26.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
4. Lindahl B, Toss H, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group: Fragmin During Instability in Coronary Artery Disease. N Engl J Med.2000;343:1139-1147.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl JMed. 2005;352:1685-1695.
6. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999; 7:169-177.
7. Whitehead AS, Brans GAP, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983; 221:69-71.
8. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-214.
9. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
10. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363—369.
11. Ridker PM, Hennekens CH, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl Y, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease-application to clinical and public health practice. Circulation. 2003; 107:499-511.
13. Torzewski J, Torzewski M, Bowyer DE, et al. C. reactive protein freque v eOlocalizes with the terminal complement complex in the intima of human corona arteries. Arterioscler Thramb Vasc Biol,1998:18:1386-1392.
14. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439 -1441.
15. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105:1890 -1896.
16. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001; 103: 2531-2534.
17. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165-2168.
18. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
19. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003; 107:1783-1790.
20. Antoni P, Kerry WS, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apoliprotein E-deficient mice. Circulation, 2004,109:647-655.
21. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64 -70.
22. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230 -235.
23. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
24. Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005; 167:923-925.
25. Mark B. Pepys. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006:440:1217-1221.
[2] Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108:2292-2297.
[3] Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
[4] Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005; 167:1139 -1148.
[5] Nilsson J. CRP: marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol. 2005;25:1527-1528.
[6] Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res. 2005;96:714-716.
[7] Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386 -1392.
[8] Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112:25-31.
[9] Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106:1439—1441.
[10]Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001 ;103: 2531-2534.
[11]Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;109:647- 655.
[12]Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res. 2005;96:714-716.
[13]Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005;167:923-925.
[14] Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
[15] Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352: 1646-1654.
[16]Nijmeijer R, Lagrand WK, Lubbers YT, Visser CA, Meijer CJ. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol. 2003;163(1):269-75.
[17]Baidoshvili A, Nijmeijer R, Lagrand WK, Hack CE. Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis. J Clin Pathol. 2002;55(2):152-3.
[18]Nijmeijer R, Lagrand WK, Visser CA. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int Immunopharmacol. 2001;1(3):403-14.
[19]Bian GX, Li GG, Yang Y, Liu RT, Ren JP. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008;31(3):458-63.
[20]Bellocci F, Biasucci LM, Gensini GF, Padeletti L, Raviele A. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study. J Cardiovasc Med (Hagerstown). 2007;8(4):293-9.
[21] Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab. 2004;24(11):1214-8.
[22]Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol. 2004;137(1):117-22.
[23]Valtchanova-Matchouganska A, Gondwe M, Nadar A. The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction. Life Sci. 2004;75(8):901-10.
[24] Mark B. Pepys, Gideon M. Hirschfield, Glenys A. Tennent, J. Ruth Gallimore, Melvyn C. Kahan, Vittorio Bellotti, Philip N. Hawkins, Rebecca M. Myers, Martin D. Smith, Alessandra Polara, Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006: 440: 1217-1222.
[25]Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest. 2008 Mar 6; [Epub ahead of print]
[26]Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. Bio Drugs. 2008;22(1):11-26.
[27]Mousli M, Turki I, Kharmachi H, Saadi M, Dellagi K.Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J Virol Methods. 2007;146(1-2):246-56.
[28]Baum P, Muller D, Ruger R, Kontermann RE. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target. 2007;15(6):399-406.
[29] Worn A, Pliickthun A. Stability engineering of antibody single-chain Fv fragments.J Mol Biol. 2001;305(5):989-1010.
[1] Black S, Kushner I, Samols D. C-reactive Protein. The Journal of biological chemistry 2004;279:48487-48490.
[2] Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-1566.
[3] Schwick HG, Haupt H. Properties of acute phase proteins of human plasma. Behring Institute Mitteilungen 1986:1-10.
[4] Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528-1536.
[5] Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology, gene expression, and host defense function. Immunologic research 1997;16:127-136.
[6] Ramadan MA, Shrive AK, Holden D, Myles DA, Volanakis JE, DeLucas LJ, et al. The three-dimensional structure of calcium-depleted human C-reactive protein from perfectly twinned crystals. Acta crystallographica 2002;58:992-1001.
[7] Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, et al. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006;48:504-511.
[8] Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999;37:265-270.
[9] Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England journal of medicine 2004;350:1387-1397.
[10]Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. Qjm 2003;96:793-807.
[11]Ikuta T, Okubo H, Ishibashi H, Okumura Y, Hayashida K. Human lymphocytes synthesize C-reactive protein. Inflammation 1986; 10:223-232.
[12]Szmitko PE, Verma S. C-reactive protein and statins: IL-8 as a molecular link? Clin Sci (Lond) 2005;108:493-495.
[13] Chun OK, Chung SJ, Claycombe KJ, Song WO. Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in u.s. Adults. The Journal of nutrition 2008;138:753-760.
[14]Kuji T, Masaki T, Li L, Cheung AK. Expression of C-reactive protein in myointimal hyperplasia in a porcine arteriovenous graft model. Nephrol Dial Transplant 2007;22:2469-2475.
[15]Makrides SC. Components of vectors for gene transfer and expression in mammalian cells. Protein expression and purification 1999; 17:183-202.
[16]Yi S, Brickenden A, Choy WY. A new protocol for high-yield purification of recombinant human prothymosin alpha expressed in Escherichia coli for NMR studies. Protein expression and purification 2008;57:1-8.
[17]Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY 1971;136:612-614.
[18]Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol 1981; 126:1820-1825.
[19]Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 1974;113:9-17.
[20]Ikuta T, Okubo H, Yukimura H, Ishibashi H. Purification of C-reactive protein. Biochemistry international 1983;6:275-282.
[21]Volanakis JE, Wirtz KW. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 1979;281:155-157.
[22] Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109:2058-2067.
[23]Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
[24] Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circulation research 2005;97:135-143.
[25] Swafford AN, Jr., Bratz IN, Knudson JD, Rogers PA, Timmerman JM, Tune JD, et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. American journal of physiology 2005;288:H1786-1795.
[26]Martensen TM. Phosphotyrosine in proteins. Stability and quantification. The Journal of biological chemistry 1982;257:9648-9652.
[27]Sahdev S, Khattar SK, Saini KS. Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Molecular and cellular biochemistry 2008;307:249-264.
[28] Cunningham F, Deber CM. Optimizing synthesis and expression of transmembrane peptides and proteins. Methods (San Diego, Calif 2007;41:370-380.
[29]Leder L, Freuler F, Forstner M, Mayr LM. New methods for efficient protein production in drug discovery. Current opinion in drug discovery & development 2007;10:193-202.
[1] Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2595-2599.
[2] Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
[3] Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England journal of medicine 1997;336:973-979.
[4] Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England journal of medicine 2000;342:836-843.
[5] Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama 2001;285:2481-2485.
[6] Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circulation research 2004;95:877-883.
[7] Suh W, Kim KL, Choi JH, Lee YS, Lee JY, Kim JM, et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochemical and biophysical research communications 2004;321:65-71.
[8] Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
[9] Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
[10] Wang Q, Zhu X, Xu Q, Ding X, Chen YE, Song Q. Effect of C-reactive protein on gene expression in vascular endothelial cells. American journal of physiology 2005;288:H1539-1545.
[11]Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. Journal of molecular and cellular cardiology 2004;36:405-410.
[12]Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
[13] Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low-density lipoprotein uptake and matrix metalloproteinase-9 release in wistar rats. Journal of lipid research 2008.
[14]Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovascular research 2003;58:186-195.
[15]Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
[16]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
[17] Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. American journal of physiology 2001 ;280:H2313-2320.
[18]Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (New York, NY 1984;226:1097-1099.
[19] Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-323.
[20]Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circulation research 2000;87:118-125.
[21]Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor- dependent monocyte recruitment in atherogenesis. Arteriosclerosis, thrombosis, and vascular biology 2000;20:2094-2099.
[22] Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical hypotheses 2004;62:499-506.
[23] Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996;348:567-572.
[24]Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-436.
[25]Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathology international 1995;45:635-641.
[26]Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
[27] Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. The Journal of experimental medicine 1999;190:1733-1740.
[28] Crow MT, Mani K, Nam YJ, Kitsis RN. The mitochondrial death pathway and cardiac myocyte apoptosis. Circulation research 2004;95:957-970.
[29] de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. British heart journal 1982;47:239-243.
[30]Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circulation research 2005;97:135-143.
[31] Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D, et al. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Molecular and cellular biochemistry 2008;310:215-226.
[32]Ikuta T, Okubo H, Ishibashi H, Okumura Y, Hayashida K. Human lymphocytes synthesize C-reactive protein. Inflammation 1986;10:223-232.
[33]Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-1932.
[34]Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110:579-587.
[35]Ikeda U, Maeda Y, Yamamoto K, Shimada K. C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovascular research 2002;56:86-92.
[36]Green DR, Reed JC. Mitochondria and apoptosis. Science (New York, NY 1998;281:1309-1312.
[37]Bialik S, Cryns VL, Drincic A, Miyata S, Wollowick AL, Srinivasan A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circulation research 1999;85:403-414.
[38]Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 1996;94:1506-1512.
[1] Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
[2] Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
[3] Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical hypotheses 2004;62:499-506.
[4] Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circulation research 2004;95:877-883.
[5] Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
[6] Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. The American journal of the medical sciences 2002;324:14-30.
[7] Benhar I, Pastan I. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin Cancer Res 1995;1:1023-1029.
[8] Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proceedings of the National Academy of Sciences of the United States of America 1991;88:8616-8620.
[9] Yang J, Moyana T, MacKenzie S, Xia Q, Xiang J. One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV/TNF-alpha) from Escherichia coli caused by the synergistic effects of glycine and triton X-100. Applied and environmental microbiology 1998;64:2869-2874.
[10]Verma R, Boleti E, George AJ. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. Journal of immunological methods 1998;216:165-181.
[11] Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer research 1992;52:6310-6317.
[12]Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer research 1992;52:3402-3408.
[13] Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989;341:544-546.
[14]DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Seminars in nuclear medicine 2005;35:143-151.
[15] Zhou J, Zhong Y. Breast cancer immunotherapy. Cellular & molecular immunology 2004;1 :247-255.
[16] Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Seminars in oncology 2004;31:196-205.
[17]Hust M, Dubel S. Phage display vectors for the in vitro generation of human antibody fragments. Methods in molecular biology (Clifton, NJ 2005;295:71-96.
[18]Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, Tayapiwatana C. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC biotechnology 2008;8:5.
[19] Tang YM, Ning BT, Cao J, Shen HQ, Qian BQ. Construction and expression of single-chain antibody derived from a new clone of monoclonal antibody against human CD14 in CHO cells. Immunopharmacology and immunotoxicology 2007;29:375-386.
[20] Liu M, Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, et al. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb. The Biochemical journal 2007;406: 237-246.
[21] Lee JJ, Chu E. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Clinical colorectal cancer 2007;7 Suppl 1:S16-20.
[22] Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer research 1993;53:1945-1951.
1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-54.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-26.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
4. Lindahl B, Toss H, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group: Fragmin During Instability in Coronary Artery Disease. N Engl J Med.2000;343:1139-1147.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl JMed. 2005;352:1685-1695.
6. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999; 7:169-177.
7. Whitehead AS, Brans GAP, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983; 221:69-71.
8. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-214.
9. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
10. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363—369.
11. Ridker PM, Hennekens CH, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl Y, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease-application to clinical and public health practice. Circulation. 2003; 107:499-511.
13. Torzewski J, Torzewski M, Bowyer DE, et al. C. reactive protein freque v eOlocalizes with the terminal complement complex in the intima of human corona arteries. Arterioscler Thramb Vasc Biol,1998:18:1386-1392.
14. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439 -1441.
15. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105:1890 -1896.
16. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001; 103: 2531-2534.
17. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165-2168.
18. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
19. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003; 107:1783-1790.
20. Antoni P, Kerry WS, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apoliprotein E-deficient mice. Circulation, 2004,109:647-655.
21. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64 -70.
22. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230 -235.
23. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
24. Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005; 167:923-925.
25. Mark B. Pepys. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006:440:1217-1221.